Neurogene Inc.
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-07-06 Financing
Neurogene Inc. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Material change report - English.pdf
Transactions 2026-07-06 Financing
Material document(s).pdf
Transactions 2026-07-02 Financing
Neurogene Inc. 3,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase 666,666 Shares of Common Stock
News release - English.pdf
Results 2026-06-29
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
News release - English.pdf
Results 2026-06-29
Neurogene Inc. Announces Positive Updated Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Material change report - English.pdf
News 2026-06-08
Neurogene Inc. Announces Completion of Dosing in EmboldenTM Registrational Trial of NGN-401 for the Treatment of Rett Syndrome
Material change report - English.pdf
Results 2026-06-08
Neurogene Announces Successful Completion of Dosing in Embolden Registrational Trial of NGN-401 for Rett Syndrome
News release - English.pdf
Results 2026-05-12
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
News release - English.pdf
Results 2026-05-12
Interim MD&A - English.pdf
Results 2026-05-12
Interim financial statements/report – English.pdf
Results 2026-04-16
Annual report - English.pdf
Results 2026-03-24 Financials
Annual report on form 10-K - English.pdf
Results 2026-03-24 Financials
Annual MD&A - English.pdf
Results 2026-03-24 Financials
Audited annual financial statements – English.pdf
News 2026-03-24
Other.pdf
Results 2026-03-24
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
News release - English.pdf
Results 2026-03-24
Neurogene Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025.
Material change report - English.pdf
News 2026-02-26
Neurogene Inc. Announces Breakthrough Therapy Designation for NGN-401 for the Treatment of Rett Syndrome
Material change report - English.pdf
News 2026-02-26
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
News release - English.pdf
News 2026-01-12
Other.pdf
Results 2026-01-12
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
News release - English.pdf
News 2025-11-14
Other.pdf
News 2025-11-14
News release - English.pdf
News 2025-11-14
Other.pdf
Results 2025-11-14 Financials
Interim MD&A - English.pdf
Results 2025-11-14 Financials
Interim financial statements/report – English.pdf
News 2025-11-13
Other.pdf
News 2025-11-13
Other.pdf
News 2025-11-13
News release - English.pdf
News 2025-11-06
Other.pdf
News 2025-11-06
News release - English.pdf
News 2025-11-06
Other.pdf
News 2025-10-09
Other.pdf
News 2025-10-09
Other.pdf
News 2025-10-09
News release - English.pdf
News 2025-08-11
Offering material - English.pdf
News 2025-08-11
Other.pdf
News 2025-08-11
Other.pdf
News 2025-08-11
News release - English.pdf
Results 2025-08-11 Financials
Interim MD&A - English.pdf
Results 2025-08-11 Financials
Interim financial statements/report – English.pdf